Accounting for business combinations: implications of Statement 141(R) for life sciences
The life sciences industry is witnessing an uptick in M&A activity. New changes in accounting rules could have a significant impact on the way in which transactions are structured as well as on an acquirer’s future earnings, financial metrics and compliance with debt covenants. This publication (pdf, 235.4kb) discusses the implications of the new rules, which apply to transactions with closing dates on or after 1 January 2009.
Accounting for clinical trials
Clinical development has always been expensive and risky. Today’s economy has only fueled these risks, as many firms reprioritize their pipelines and increase their reliance on clinical research organizations (CROs) to cut costs. In this bio*link, we summarize common accounting issues related to clinical activities (pdf, 142kb) and provide examples of good internal controls. We also offer useful information to help benchmark your internal controls against peers.
Pulse of the industry 2009: medtech review
Medtech emerged from the recession relatively healthy, but long-term challenges remain: a funding drought and an uncertain global regulatory and reimbursement environment. What’s in store for the medtech industry? In our latest report, we evaluate the industry’s performance — financial, financing and transaction activity — and provide not-to-be-missed insights from leading medtech organizations.
Lessons from change: the life sciences industry
How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment.